Deep Roots and Tangled Branches
By Troy Duster,
Chronicle of Higher Education
| 02. 03. 2006
People who know their biological parents and grandparents typically take the information for granted. Some have a difficult time empathizing with the passionate genealogical quests of adoptees and, increasingly, products of anonymous sperm banks and other new technologies where one or both genetic contributors are unknown. In recent years, new legislation has enabled people to search for information about genetic progenitors - even in cases where there had been a signed agreement of nondisclosure. The laserlike focus of that search can be as relentless as Ahab's hunt for the white whale.
Mystery of lineage is the stuff of great literature. Mark Twain made use of it for biting social commentary in his Pudd'nhead Wilson, a story about the mix-up of babies born to a slave and a free person. Sophocles, Shakespeare, Molière, and Dickens built grand tragedy and enduring comedy on the theme. In England in 2002, a white Englishwoman gave birth to mixed-race twins after a mix-up at an in vitro fertilization clinic. Imagine what Shakespeare would have done with that!
If one person's passions can be so riled...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...